TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use, carrying the triazene group as the cytotoxic principal. Using a standard 3 + 3 design, a phase I study was performed in tumour bearing dogs to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic (PK) profile of TriN 2755. Thirty dogs were included in the study. TriN 2755 was administered over 20 min on two consecutive weeks per month for a total of three cycles. The starting dose was 25 mg kg −1 and the MTD was 74.6 mg kg −1 . Three dogs experienced DLT, which was characterized by gastrointestinal adverse events. The PKs of TriN 2755 and its main metabolites in plasma and sputum are described in a two-compartment model. The response rate for 19 of 30 dogs was 47.3% (six partial remission, three stable disease) and the median progression-free interval (PFI) for the responders was 47 days (range: 21-450 days).
Introduction
Triazenes are established alkylating chemotherapeutic compounds in clinical use in humans 1,2 and dogs 3 -5 , which can induce apoptosis in susceptible tumours and act as antimetastatic agents. 6, 7 The triazene drugs that are of main clinical interest include dacarbazine (DTIC) and temozolomide (TMZ). These two compounds have similar chemical, physical, antitumour and mutagenic properties. 6 TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use with a unique chemical structure, carrying the triazene group as the cytotoxic principal. Although TriN 2755 belongs to the group of triazene compounds, it differs due to its physicochemical properties as well as its potent antineoplastic activity. TriN 2755 is highly † This study was presented in part as abstracts (oral presentation) at the Annual Conferences of the Veterinary Cancer Society in Las Vegas, NV, USA, October 2012 and Minneapolis, MN, USA, October 2013. photostable and hydrophylic, showing potent dose dependent antitumour activity in a variety of human cancer xenografts in murine models. 8 Specifically, in these studies melanoma MEXF 462, colon adenocarcinoma CXF 280 and mammary MAXF 401 tumour models experienced a long lasting therapeutic effect and at the end of these studies most tumours were either in partial remission or in complete remission. 8 In addition, TriN 2755 was more effective than TMZ in melanoma MEXF 462 murine models, which was tested in parallel. 8 The effects of TriN 2755 were also tested in DTIC resistant melanoma MEXF276 and MEXF1341 xenografted mice. A significant inhibition in the tumour growth as well as prevention of metastasis formation was observed (Investigator's Brochure, Trin Therapeutics GmbH, Düsseldorf, Germany).
The pharmacokinetic (PK) studies in rats and healthy beagle dogs showed a dose dependent increase of the plasma concentration and area under the curve (AUC) of TriN 2755, following IV administration of the drug. TriN 2755 is well tolerated in these species (Investigator's Brochure, Trin Therapeutics GmbH).
The in vitro and in vivo PK studies revealed that TriN 2755 is a prodrug activated by the cytochrome P450 enzymes. 9, 10 The main metabolites of TriN 2755 are M1 and M4 (Figure 1 ). M1 still carries the triazene group and it is more active in vitro than the prodrug TriN 2755. 9 The aim of this study was to perform a phase I clinical trial in tumour bearing dogs to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), the adverse events (AE) profile and the pharmacokinetic (PK) profile of TriN 2755. Additionally, tumour response was monitored and assessed as a secondary goal.
Material and methods

Patient eligibility criteria
Dogs presented to the Vetsuisse Faculty, University of Zurich, Switzerland with histologically or cytologically confirmed neoplastic disease were prospectively enrolled in this study if they were refractory to standard of care treatment, if the owner declined other treatment, or if no established standard of care existed. In order to meet the inclusion criteria, dogs required to have a clinical examination, complete blood count (CBC), serum biochemistry profile, +/− thoracic radiographs and/or abdominal ultrasound (depending on the location of the neoplastic disease). In order to be able to receive chemotherapy, dogs required adequate haematological function (haematocrit ≥ 30%, thrombocytes ≥ 10 0000 μL, neutrophils ≥ 2000 μL) and absence of any serious systemic disorder incompatible with the study. However some patients were included in the study regardless of moderate haematological (such as thrombocytopenia and anaemia) and/or moderate clinically abnormal conditions, if the haematological abnormalities were due to the tumour and if the owner desired a 'last chance' in case of a patient in clinically bad condition due to the tumour. Prior chemotherapy treatment had to be terminated at least 3 weeks before entering the study. Written owner's consent was obtained and the study was approved by the Animal Ethics Council of the Canton of Zurich, Switzerland.
Study design and drug administration
This trial was a phase I dose-escalating, open-label assessment of safety and toxicity of TriN 2755 in client-owned dogs with spontaneously occurring tumours. The assessment and treatment was initially carried out on three dogs, in dose-escalating cohorts using a traditional 3 + 3 design. 11, 12 Escalation was performed according to Vail 12 where the dose was escalated if none of three dogs of one dose cohort developed dose-limiting toxicity (DLT). If one of the three dogs of a cohort experienced DLT, at least three more dogs were included at the same dose level. Dose escalation was stopped, if two or more dogs of a cohort of three, or an extended cohort of six patients, respectively, developed DLT; the dose of this cohort was the maximally administered dose. The maximally tolerated dose (MTD) was defined as the dose of the highest dose level in which no more than one of six dogs develops DLT. 12 The escalation steps occurred in increments of 20% of the previous dose. Starting dose was 25 mg kg −1 , based on 50% of the MTD according to experimental beagle data (Investigator's Brochure, Trin Therapeutics GmbH). 12 The treatment schedule consisted of IV administration of the drug over 20 min on two consecutive weeks per month for a total of three cycles. The dogs were evaluated every week for AE and tumour response. If no progression was noted at the end of the three cycles, treatment with TriN 2755 was continued at the same dose level but on an every two weeks schedule. TriN 2755 (Trin Therapeutics GmbH) for in vivo administration was provided as a powder; the powder was diluted with sterile water for injection, to obtain a concentration of 2 mg mL −1 . The calculated dose was given as an IV infusion in parallel with 250 ml 0.9% saline over a 20-min interval through the PhaSeal system. Supportive care (e.g. antiemetics and or antidiarrhoeal drugs) was administered after occurrence of AE and was provided prophylactically after the next administration of drug. Maropitant (2 mg kg −1 , semel in die (SID), orally or subcutaneously) or Ondasentron (0.1-0.2 mg kg −1 , bis in die (BID), orally or IV) was given against nausea and emesis, and Metronidazole (15 mg kg −1 , BID, orally or IV) against diarrhoea. Medication allowed for disease unrelated comorbidity and/or further supportive care included steroids and non-steroidal anti-inflammatory drugs (NSAIDs). Antibiotics were prescribed in case of additional infection related or unrelated to the tumour (e.g. urinary tract infection, infection of tumour). Analgesics such as tramadol or NSAID for tumour-associated pain were allowed.
Toxicity assessment
Dogs were evaluated for toxicity weekly before each treatment, and one week after the last chemotherapy; evaluation of toxicity to determine the MTD was done after the first dose only. The AE were monitored by performing a physical examination, CBC and serum biochemistry at each scheduled appointment. Owners were asked to maintain a diary on animal's performance at home. Blood results and signs of AE were graded according to the VCOG-CTCAE v1.1. 13 Toxicity criteria considered as unacceptable which lead to discontinuation of the trial were defined as ≥ grade 3 toxicity, except haematological toxicities, where ≥ grade 4 was considered unacceptable. The trial also included heavily pretreated patients with an advanced stage of disease, thus a baseline status of symptoms using the same criteria was recorded for each dog before the trial started.
Tumour response assessment
Owing to the dose-escalating nature of this trial, response to treatment was only a secondary goal.
Tumour size (locoregional and systemic) was assessed at study entry, before each drug administration if the tumour was measurable without the confirmation of diagnostic imaging (e.g. peripheral lymphnodes, skin tumours), and 3 weeks after the last treatment by means of calliper measurements and additional diagnostic imaging according to the tumour. For intra-thoracic and intra-abdominal tumours re-evaluation (thoracic radiographs and eventually abdominal ultrasound) was also performed in the fifth or sixth week after the first administration of TriN 2755. Response was assessed as follows: in dogs with disseminated histiocytic sarcoma (DHS) and other solid tumours, response was measured according to the revised RECIST guideline v1.1. 14 The sum of diameters of all target lesions was calculated and reported as the baseline sum diameter. In dogs with multicentric lymphoma, criteria according to the VCOG consensus document for peripheral nodal lymphoma were used. 15 Lymph nodes were measured using callipers and the mean sum of the longest diameter of a maximum of five target lesions was calculated. According to both guidelines, responses were considered to be complete if all target lesions had disappeared (or lymph nodes were of normal size, respectively), partial remission (PR) if a 30% decrease of the sum of target lesion diameters occurred, or progressive disease (PD) if new lesions occurred or if there was an increase of at least 20% in the sum of target lesion diameters, taking as reference the smallest sum of the study. Dogs that showed neither sufficient shrinkage, to qualify for PR, nor sufficient increase to qualify for PD were considered to have stable disease (SD). 14,15
Pharmacokinetic evaluation
The results from a toxico-PK study in beagle dogs (Investigator's Brochure, Trin Therapeutics GmbH) and the early results of an ongoing phase I study in humans 10 lead us to the decision to investigate the PKs of TriN 2755 in this trial in each dog for the first dose-group and then in one dog of the further dose-groups. Ethylenediaminetetraacetic acid (EDTA) blood samples were collected before and at 0.5, 1, 2, 3 and 4 h after IV TriN 2755 infusion. The samples were put immediately on ice and centrifuged for 10 min at 4 ∘ C by 2000 × g. The supernatant plasma was removed and stored at −80 ∘ C until further analysis. In addition, samples from emesis (four in total) were collected and stored at −80 ∘ C until further analysis. Plasma and emesis samples were analyzed by a validated liquid chromatography-mass spectrometry-high performance liquid chromatography (LC-MS-HPLC) method; in brief, a rapid and sensitive LC-MS method combined with ultraviolet (UV) detection was developed and validated for the quantitative determination of TriN2755 and its metabolites from aliquots of EDTA plasma. The sample extraction and cleaning-up involved a simple solid phase extraction. Chromatographic separations were achieved on a reversed phase C18 column eluted at a flow-rate of 1.00 mL min −1 on a gradient of formic acid, methanol and acetonitrile. The overall cycle time of the method was 40 min. The monitored masses using electrospray ionisation were 193, 198, 214, 215 and 256 (m/z) for TriN2755 and its putative metabolites, respectively. For UV detection, a wavelength of 300 nm was used. The calibration curves were linear over the range 3.00-400 ng mL −1 with the lower limit of quantification (LLQ) validated at 3.00 ng mL −1 for MS detection and between 400 ng mL −1 and 100 μg mL −1 using UV detection at 300 nm. The results obtained during the validation of this method fulfil all requirements and recommendations, generally accepted for bioanalytical studies. 16 -18 The within-run and between-run precisions, also at the levels of LLQ and upper limit of quantification (ULQ), ranged between 3.0 and 10.8% [as (%) coefficient of variation (cv)], whereas the accuracy [as (%)bias] ranged from +1.1 to −8.6%. The within-run and between-run precisions in this range were within 4.99%, whereas the accuracy ranged 95.8 to 100.3%. The method was successfully applied to samples derived from this clinical phase I study.
Statistical analysis
Plasma PK parameters, AUC, maximum concentration (C max ), time to maximum concentration (T max ) and elimination half-life (t 1/2 ) for TriN 2755 and its metabolites were calculated using a two-compartment disposition model (programme TOPFIT 2.0). 19 The linear-logarithmic trapezoidal method was used to calculate AUC, and apparent t 1/2 was calculated by linear least squares regression after logarithmic transformation of the terminal concentrations.
Results
Patient characteristics
A total of 30 client-owned dogs were included in the study between April 2011 and July 2013. The patient population consisted of dogs of various breeds; the most common breed was the Bernese Mountain Dog (BMD) (n = 13). Other breeds included are shown in Table 1 . Median age upon study entry was 8.3 years (range: 4.3-14.6 years) and median weight 35.7 kg (range: 8.7-60.1 kg). Nine dogs were intact (three females, six males), 11 were castrated males and 10 spayed females. Different types of tumours were included; the most common primary tumour was histiocytic sarcoma (HS) (n = 14). Thirteen dogs had the disseminated form (DHS) and one had the localized form (LHS). The most common anatomical location for the DHS was the lung (n = 8), followed by spleen (n = 3), tracheobronchial lymphnodes (n = 2), liver (n = 2), mediastinal and abdominal lymphnodes, eye, bone and kidney. The dog with the LHS had the tumour in its right elbow region. Other tumours included are shown in Table 1 . More than half of the dogs had not received any prior treatment (n = 18), whereas 12 dogs of the study had either chemotherapy (six with malignant lymphoma 
Drug administration
Patients were divided into eight different dose groups from 25 to 89.5 mg kg −1 with increments of 20%. The groups consisted of three dogs; one of the three dogs from the fifth group experienced DLT and three additional dogs were added to this group. None of the three additive dogs experienced any DLT, thus the dose escalation was continued. At the MTD level three confirmatory patients were added. Thirty-three (10/30) of the enrolled patients completed the three cycles as planned and two of these continued treatment due to partial remission or SD; 2 patients with DHS had 18 and 9 applications of TriN 2755, respectively. Nineteen dogs received TriN 2755 only 2-4 times because of tumour progression or because of owner's wish to discontinue (e.g. dogs in end-stage disease at entry without signs of improvement). This applied to the patients that had two applications of TriN 2755. One dog of the study received TriN 2755 only once because it died 8 days after the first chemotherapy; the cause of death in this case was unrelated to the tumour or the chemotherapeutic agent. A total of 8 of 30 dogs received concurrent NSAIDs and 11 of 30 received steroids (oral prednisolone). Of the six lymphoma patients only one received steroids during the treatment with TriN 2755.
Toxicity assessment
The toxicity was assessed after the first administration of TriN 2755. Over the 12-week period, overall side effects were mild and rarely dose-limiting, as summarized in Table 2 .
Haematological and biochemical parameters
Haematological and biochemical changes were not observed in any of the patients receiving the study drug. Of 30 dogs 14 had already haematological and biochemical abnormalities at the time of inclusion either due to concurrent disease or due to causes related to the tumour.
Gastrointestinal effects
Main gastrointestinal AE were anorexia, diarrhoea, nausea and vomiting beginning within 24 h after the end of the infusion of TriN 2755. In this study, 3 of 30 dogs experienced dose-limiting toxicities due to diarrhoea and vomiting. When occurrence of gastrointestinal AE was detected after the first drug administration, supportive care was administered in 24 of 30 dogs. Not all AE were considered to be related to TriN 2755 administration; in some dogs, observed toxicities were rather related to disease progression or to treatment-unrelated concurrent morbidities.
Other effects
Grades 1-2 fatigue was observed in 19 of 30 dogs after the first administration of TriN 2755. Table 2 provides a summary of the AE noted after the first administration of the study drug approximately within 24 h.
Maximally tolerated dose
TriN 2755 was well tolerated up to a dose of 74.6 mg kg −1 . At the next higher dose level of 89.5 mg kg −1 , two of three dogs showed doselimiting gastrointestinal toxicity grade 3, therefore the cohort study stopped. MTD for TriN 2755 application was determined to be 74.6 mg kg −1 .
Tumour response assessment
Preliminary antitumour activity was examined only in patients that have completed the first cycle and received at least three times TriN 2755. In addition, one dog (patient 29) with metastatic lung adenocarcinoma receiving four times TriN 2755 was excluded from the response-analysis due to difficulties in evaluating the tumour because of an almost continuous production of free fluid in the thorax; therefore, the response was All three dogs with SD disease completed the three cycles of TriN 2755 (treatments ranged: 6-9); one BMD with DHS (splenic form, PFI 139 days), one dog with LHS (PFI 117 days) and one dog with gastric adenocarcinoma (PFI 126 days).
Six of 10 dogs with PD were BMD with DSH; all dogs completed three cycles of TriN 2755 (median PFI 78.5 days, range: 63-91 days). Table 1 provides a summary of the patients and the response by cohort.
Pharmacokinetics of TriN 2755 and its metabolites
The PK of TriN 2755 and its main metabolites in this infusion protocol is well described with a two compartment disposition model. An example is given in Figure 2 ; one dog of cohort 7 was treated with 74.6 mg kg (MTD) TriN 2755. TriN 2755 and its main metabolites M1, M3 and M4 were analyzed within 4 h after start of the slow bolus injection. By using a two compartment model, extrapolation to infinity was possible. AUC as well as C max of the given drug TriN 2755 increased in a linear manner with dose (r 2 = 0.92 and 0.86, respectively). We obtained a higher deviation from linearity in AUC calculation for the main metabolites M1 and M4 (r 2 = 0.72 and 0.70, respectively), and even a worse correlation for C max calculation (r 2 = 0.39 and 0.36, respectively). T max of TriN 2755 was obtained at the end of infusion (about 20 min), the calculated T max for M1 was 0.82 ± 0.08 h (mean ± SD), about 30 min after end of infusion. The calculated T max of metabolite M4 was 1.64 ± 0.49 h, more than 75 min after end of infusion. Terminal half-lives were 0.60 ± 0.18 h for TriN 2755, 0.82 ± 0.09 h for M1, and 1.34 ± 0.43 h for M4, respectively. PK calculations for metabolite M3 were not possible in all cases. Therefore, single values are not presented (Table 3) .
Analysis of sputum
Six dogs of the study vomited orange/red fluid 2-6 h after the administration of the study drug. All these dogs received TriN 2755 at a dose equal or more than 62.2 mg kg −1 . Four samples of sputum from three dogs were collected for further investigation. Two of 4 samples were from the same dog (patient 21); collected in the first 2 h and the second 5.5 h after the administration of TriN 2755. The pH for the first sample was 7.6 and for the second 2.57. The other two samples were collected from two different patients (patient 23, 26) and at the same time a blood sample was drawn; the pH of the sputum from the patient 23 and 26 were 7 and 7.7, respectively. TriN 2755 and its metabolites were detected in all four sputum samples.
Discussion
According to this phase I trial, the maximum tolerated IV dose of TriN 2755 in dogs was determined to be 74.6 mg kg −1 . The toxicities related to the drug were in general mild in severity and include fatigue and gastrointestinal upset; vomitus, anorexia, nausea and diarrhoea (Table 2 ). It is described that dogs receiving DTIC and Temozolamide show primarily haematological and gastrointestinal AE. 3 -5 However none of the dogs in this study experienced any haematological changes related to the drug administration during or at the end of the study. The DLT is characterized by gastrointestinal AE and it did not exceed grade 3. On the basis of results of this study 3 patients in total experienced DLT; two dogs (patient 15, 26) experienced grade 3 diarrhoea and one dog (patient 27) showed grade 3 vomitus.
Cancer patients in a human phase I study tolerated TriN 2755 intravenously up to a total dose of 6000 mg. Only grades 1-2 fatigue, vomitus and anorexia were observed in human patients receiving doses of TriN 2755 ranging between 25 and 6000 mg in total. None of the humans patients experienced haematological toxicity. 10 In contrast, dosages of TriN 2755 higher than 74.6 mg kg −1 (which correlates to 3000-4500 mg in total) given to our canine patients resulted in grade 3 gastrointestinal AE. Hence, the tolerated dose in dogs seems to be lower than in man. Similar to DTIC, TriN 2755 is an alkylating agent activated in the liver by CYP 450 enzymes. 6 M1 and M4 are the main metabolites of TriN 2755. Whereas M1 is still carrying the triazene group, M3 and M4 are the anilines obtained after enzymatic demethylation of the triazene group of TriN 2755 and M1, respectively. 9 The inactive metabolite M4 is formed either after enzymatic demethylation of the triazene group of M1 via Cyp1A1, CYP1A2, and CYP2E1 (analogous to DTIC 20 , data not shown) or by hydrolysis of metabolite M3 (Figure 1) . In humans and dogs the relationship of AUC and C max to drug dose is linear. In addition, the extent of formation of the active metabolite M1 from TriN 2755 is higher than 50% in both species. The inactive aniline metabolite M3 is formed in humans and dogs to negligible amounts (less than 1% and 0.1%, respectively; data not shown). Whereas the aniline metabolite M4 is further metabolized via N-acetylation in humans (data not shown), the absence of N-acetyltransferases in dogs 21, 22 leads to fundamental differences in the PK profile of M4 between human and dog. By comparing the PK profile of TriN 2755 and its metabolites in dogs and humans, there are 10-fold higher concentrations of the aniline metabolite M4 of TriN 2755 detectable in dogs after a comparable dose of 74.6 mg kg −1 in dogs (absolute dose = 3453 mg) and 73.2 mg kg −1 (flat dose = 6000 mg) in humans. This might be an explanation for the decreased tolerance of TriN 2755 in dogs (Figure 3) . M4 is the suspected metabolite being responsible for AE. Further in vitro studies are necessary to explore this hypothesis. In addition, further work is required with more animals to evaluate the poor coefficient of correlation seen between AUC and C max relative to dose, for M1 and M4 metabolites. These phenomena may simply be explained by variation in inter-individual metabolic activity which could be explored further.
Six dogs of this study receiving a dose of TriN 2755 equal or more than 62.2 mg kg −1 vomited a red/orange fluid. Four sputum-samples from three of these six dogs were further evaluated; TriN 2755 and its main metabolites were detected in all four samples and the pH for 3/4 sputum-samples ranged between 7.0 and 7.7. These results might suggest that the coloured sputum is hepatic bile and TriN 2755 and its metabolites enter the hepatobiliary circulation, considering that the normal hepatic bile of the dogs has a colour golden yellow to orange and the pH ranges between 7.0 and 7.8. 23 Further investigation is needed to verify this hypothesis. This study was a dose-escalating phase I clinical trial; therefore, the response was only a secondary goal. Although most of the patients were treated with TriN 2755 at a dose lower than the MTD, which is one of the limitations of a phase I clinical trial using the "3 + 3" design 11 , and suffered from tumours that are not easy to treat (e.g. DHS, gastric adenocarcinoma, subcutaneous malignant melanoma), the responses that were registered in this study are promising. Twelve dogs from our study were BMDs having DHS. DHS, previously known as malignant histiocytosis, is a malignancy of histiocytic cell origin. 24 -26 DHS arises from the dendritic antigen-presenting cells. 26 -28 Bernese Mountain Dogs, Flat-coated Retrievers, Labrador Retrievers and Rottweilers are breeds that are predisposed to HS, with the BMD showing a heritable predisposition to DHS. 26,28 -34 DHS is a rapidly progressing multisystemic disease with a poor prognosis. 25 Therefore, the recommended treatment is systemic chemotherapy. 24 In one study Lomustine (CCNU) was given in 59 dogs with HS. The response rate was 46% and the median survival time (MST) for the dogs that responded was 172 days. The same study showed that dogs with splenic involvement had a worse prognosis with a MTS of 58 days. 30 The course of the disease for the BMDs is referred to be even worse than other breeds according to two studies, giving a MST of between 30 and 49 days. 31, 32 Remarkably, one BMD with DHS showed partial remission for 450 days, one BMD had disease stabilization for 139 days, and a Golden Retriever for 117 days, indicating that TriN 2755 might have antitumour activity against malignant tumours of histiocytic origin. In summary, this study showed a safe and tolerable dose of TriN 2755 for IV use. The AE were mild in severity and limited in fatigue and gastrointestinal upset. The response rates of this phase I clinical trial showed promising advantages of the use of this triazene, but a phase II clinical trial is needed to determine the efficacy of this drug.
